Medtronic PLC (MDT) Shares Bought by Parkside Financial Bank & Trust
Parkside Financial Bank & Trust lifted its holdings in Medtronic PLC (NYSE:MDT) by 22.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,146 shares of the medical technology company’s stock after purchasing an additional 210 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Medtronic PLC were worth $102,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Israel Discount Bank of New York acquired a new position in shares of Medtronic PLC in the 1st quarter valued at approximately $117,000. Birch Hill Investment Advisors LLC acquired a new position in shares of Medtronic PLC in the 1st quarter valued at approximately $120,000. Farmers National Bank acquired a new position in shares of Medtronic PLC in the 1st quarter valued at approximately $121,000. Norway Savings Bank grew its position in shares of Medtronic PLC by 2.7% in the 2nd quarter. Norway Savings Bank now owns 1,427 shares of the medical technology company’s stock valued at $127,000 after purchasing an additional 38 shares during the period. Finally, Proficio Capital Partners LLC grew its position in shares of Medtronic PLC by 33.3% in the 1st quarter. Proficio Capital Partners LLC now owns 1,811 shares of the medical technology company’s stock valued at $153,000 after purchasing an additional 452 shares during the period. Institutional investors and hedge funds own 80.75% of the company’s stock.
Shares of Medtronic PLC (MDT) opened at 82.03 on Monday. The company has a 50-day moving average price of $82.66 and a 200 day moving average price of $83.60. The firm has a market capitalization of $111.72 billion, a price-to-earnings ratio of 27.61 and a beta of 1.03. Medtronic PLC has a 1-year low of $69.35 and a 1-year high of $89.72.
Medtronic PLC (NYSE:MDT) last posted its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.04. Medtronic PLC had a return on equity of 12.92% and a net margin of 13.75%. The business had revenue of $7.39 billion during the quarter, compared to analysts’ expectations of $7.44 billion. During the same period in the previous year, the business earned $1.03 earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. On average, equities research analysts predict that Medtronic PLC will post $4.76 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 29th will be given a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a yield of 2.24%. The ex-dividend date of this dividend is Thursday, September 28th. Medtronic PLC’s payout ratio is 61.95%.
Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Medtronic PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. BidaskClub lowered Medtronic PLC from a “hold” rating to a “sell” rating in a research report on Saturday, August 26th. UBS AG reiterated an “overweight” rating on shares of Medtronic PLC in a research report on Thursday, August 24th. Jefferies Group LLC decreased their price objective on Medtronic PLC from $103.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. Finally, Barclays PLC decreased their price objective on Medtronic PLC from $94.00 to $92.00 and set an “overweight” rating for the company in a research report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $88.78.
In other news, EVP Bryan C. Hanson sold 12,000 shares of the company’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $88.57, for a total value of $1,062,840.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard H. Anderson acquired 5,600 shares of the business’s stock in a transaction dated Wednesday, June 21st. The stock was purchased at an average price of $88.90 per share, with a total value of $497,840.00. Following the completion of the acquisition, the director now directly owns 71,910 shares in the company, valued at approximately $6,392,799. The disclosure for this purchase can be found here. 0.31% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/11/medtronic-plc-mdt-shares-bought-by-parkside-financial-bank-trust.html.
Medtronic PLC Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.